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Abstract
Introduction: Treat-all is being implemented in several African settings, in accordance with 2015 World Health Organisation
guidelines. The factors known to undermine adherence to antiretroviral therapy (ART) may change in the context of Treat-all,
where people living with HIV (PLHIV) increasingly initiate ART at earlier, asymptomatic stages of disease, soon after diagnosis.
This paper aimed to examine the asymptomatic PLHIV’s experiences engaging with early ART initiation under the Treat-all pol-
icy, including how they navigate treatment-taking over the longer term.
Methods: A longitudinal qualitative study was conducted within a Medecins Sans Frontieres/Ministry of Health Treat-all pilot
in Shiselweni, southern Eswatini. The Treat-all pilot began in October 2014, adopted into national policy in October 2016. Par-
ticipants were recruited purposively to include newly diagnosed, clinically asymptomatic PLHIV with a range of treatment-tak-
ing experiences, and healthcare workers (HCW) with various roles. This analysis drew upon a sub-sample of 17 PLHIV who
had been on ART for at least 12 months, with mean 20 months on ART at first interview, and who undertook three interviews
each. Additionally, 20 HCWs were interviewed once. Interviews were conducted from August 2016 to September 2017. Data
were analysed thematically using coding, drawing upon principles of grounded theory, and aided by Nvivo 11.
Results: It was important for PLHIV to perceive the need for treatment, and to have evidence of its effectiveness to motivate
their treatment-taking, thereby supporting engagement with care. For some, coming to terms with a HIV diagnosis or re-inter-
preting past illnesses as signs of HIV could point to the need for ART to prevent health deterioration and prolong life. How-
ever, others doubted the accuracy of an HIV diagnosis and the need for treatment in the absence of symptoms or signs of ill
health, with some experimenting with treatment-taking as a means of seeking evidence of their need for treatment and its
effect. Viral load monitoring appeared important in offering a view of the effect of treatment on the level of the virus, thereby
motivating continued treatment-taking.
Conclusions: These findings highlight the importance of PLHIV perceiving need for treatment and having evidence of the dif-
ference that ART is making to them for motivating treatment-taking. Patient support should be adapted to address these con-
cerns, and viral load monitoring made routinely available within Treat-all care, with communication of suppressed results
emphasized to patients.
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1 | INTRODUCTION
Treat-all is being implemented in several African settings,
accordant with 2015 World Health Organisation (WHO)
guidelines recommending regular HIV testing and immediate
offer of antiretroviral therapy (ART) for all those diagnosed
HIV-positive, irrespective of immunological status [1]. To con-
tribute towards reduced HIV incidence and the hoped-for
elimination of AIDS, Treat-all requires engagement of individ-
ual people living with HIV (PLHIV) with HIV testing, prompt
initiation of ART and continued lifelong treatment [2-5].
However, shortfalls exist across the treatment and care cas-
cade [6-8].
There is extensive research examining adherence to ART in
African settings under previous treatment guidelines, high-
lighting the individual, social and structural factors influencing
engagement with treatment and care among PLHIV [9-11].
Motivation for adherence may be stronger when patients are
very sick at ART initiation, as the effects of ART in enabling a
return to health and strength can create a sense of need for
treatment and belief in its efficacy, and past illness experi-
ences are drawn upon to motivate continued treatment-taking
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[12,13]. Many of these factors change in the Treat-all context,
where PLHIV are initiating ART at earlier, asymptomatic
stages of disease, where the time between diagnosis and ART
initiation may be expedited, and the length of time on ART
may eventually be greater than previously.
Evidence from Prevention of Mother to Child Option-B+
(Option-B+) suggests retention in care among women on
Option-B+ is lower than among women starting ART for their
own health [14-16]. HIV status acceptance, treatment readi-
ness and perceived need for treatment in the absence of
symptoms can undermine pregnant and lactating women’s
retention, with some disengaging from care once their per-
ceived objective of protecting the baby is fulfilled [17-19].
While these findings provide important insights into under-
standing how asymptomatic PLHIV may respond to ART, the
experiences of pregnant and lactating women are likely to
differ from those of the general population.
It is important to understand PLHIV’s experiences with
Treat-all care to ensure programmes correspond to their needs,
and can adequately and appropriately support them to engage
with treatment and care to improve health outcomes [20-22].
Additionally, from a public health perspective, suboptimal adher-
ence among growing cohorts of asymptomatic patients could
lead to drug resistance, which has been highlighted as a critical
threat to eliminating AIDS by 2030 [23-26]. This heightens the
importance of understanding how treatment-taking is experi-
enced by asymptomatic PLHIV enrolled in Treat-all care.
We examine asymptomatic PLHIV’s experiences engaging
with Treat-all care in the Kingdom of Eswatini (formerly
named Swaziland), including how treatment-taking is navigated
and motivated over the longer term (at least 12 months after
initiation).
2 | METHODS
2.1 | Study design
This paper draws on data that were collected between August
2016 and September 2017, within a longitudinal qualitative
study on the experiences of asymptomatic PLHIV enrolled in
chronic HIV care under the Treat-all policy in Eswatini.
2.2 | Study setting
This study took place in the Shiselweni region of Eswatini,
where Medecins Sans Frontieres (MSF) and the Ministry of
Health (MoH) collaboratively provide decentralized HIV and
tuberculosis care since 2007, with a Treat-all implementation
pilot beginning in October 2014. Eswatini has the highest
reported HIV prevalence worldwide, estimated at 35% among
women and 19% among men aged 15 to 49 years [27], with
heterosexual sex being the main transmission route [28]. Men
are generally infected at older age than women, and HIV
prevalence peaks at 54% among women aged 35 to 39 years
and 49% among men aged 45 to 49 years [29].
The Treat-all pilot project was implemented in the predomi-
nantly rural Nhlangano health zone, with eight primary health-
care clinics (largely rural, offering integrated HIV services) and
one secondary health facility (urban, offering HIV care within
a specific HIV-related care department or as part of antenatal
care). Patient enrolment to the pilot ended on 31 March
2016, with Treat-all then becoming the standard of care in
Nhlangano, and adopted into national policy in October 2016.
Within the pilot project, prompt ART initiation was offered on
the day of facility-based HIV care registration. Forty-nine per
cent of patients initiated on the same day as enrolment to
HIV care, and the majority of those who deferred initiated
ART at a median of 10 days [30]. Routine viral load monitor-
ing was available at six months on ART and annually there-
after if results showed viral suppression. Communication of
viral load results was prioritized for those with unsuppressed
results, who were offered enhanced adherence counselling.
2.3 | Participant recruitment
PLHIV participants were identified and recruited purposively
to include only those recorded as newly diagnosed (within
three months of enrolment to care) and considered clinically
asymptomatic (WHO disease stage 1 and CD4 count
≥500 cells/mm3), using the Treat-all patient database as a
sampling frame. For the purposes of this analysis, we drew
upon a subset of the study sample to include those who were
enrolled at the beginning of the Treat-all pilot, from October
2014 to June 2015, and who therefore would have been
enrolled in at least 12 months at the time of first interview
(see Table 1). This allowed examination of longer term, sus-
tained engagement with treatment and care in the context of
Treat-all. We anticipated that recruiting young men (aged 16
to 25) would be challenging, as very few young men are
infected with HIV in Eswatini, and as men often access treat-
ment and care later in this setting.
Healthcare worker (HCW) participants were sampled pur-
posively, to include those from all the nine clinics involved in
the pilot, both MoH and MSF staff members, and a range of
different treatment and care-related positions, such as adher-
ence counsellor (HIV-positive peer supporters), nurse, nurse
supervisor and doctor (Table 2).
Participants were recruited until data saturation was evi-
denced, that is, when adding further participants did not gen-
erate new findings relating to the particular topic or theme
being investigated [31].
2.4 | Data collection and analysis
Repeat in-depth interviews with PLHIV participants aimed to
gain insight into changes in participants’ accounts of their
experiences with Treat-all over time, and to build trust and
rapport between interviewer and interviewee, enabling access
to alternative layers of participants’ narratives beyond those
participants may deem to be socially desirable. Interviews
were based on topic guides and were primarily participant-led,
with first interviews focusing on the participant’s life history,
second their experiences of HIV testing and diagnosis, offer of
treatment and experience starting ART. Subsequent interview
(s) explored ongoing treatment-taking, and revisited topics
explored in earlier interviews to gain greater depth of insight
and to explore any changes. Interviews were conducted from
August 2016 to September 2017, the majority being held at
participant homes, or at an alternative site if preferred.
Interviews with HCW participants explored views and expe-
riences relating to Treat-all implementation and providing
treatment and care to asymptomatic patients. These were
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one-time interviews conducted during February and March
2017, held in the clinics where HCWs worked.
Informed written consent was sought prior to all interviews,
including for audio-recording, which was re-visited verbally at
subsequent interviews for PLHIV participants. Interviews
averaged 80 minutes, ranging from 50 minutes to 1 hour 40
minutes. Pseudonyms are used to protect participant confi-
dentiality.
Detailed field notes were completed for each interview, and
audio-recordings were translated and transcribed. Data were
analysed thematically using coding to identify patterns, cate-
gories and themes that emerged from participant accounts,
drawing upon principles of grounded theory to raise findings
to a conceptual level [32,33]. Initial codes were organized into
a coding framework, forming the basis of continued analysis in
Nvivo 11, which was developed and adapted as data collection
and analysis progressed. Data collection and analysis followed
an iterative process, enabling topic guides to be adapted to
further probe emerging themes.
Ethics approval was obtained from the Eswatini Scientific
and Ethics Committee, the London School of Hygiene and
Tropical Medicine and MSF Ethics Review Boards prior to
study commencement.
3 | RESULTS
3.1 | Study participants
Selecting those enrolled to Treat-all from October 2014 to
June 2015 from the sample, seventeen PLHIV participants
were eligible for inclusion in this analysis, including nine
women and eight men, with fifteen interviewed three times,
one interviewed four times and one interviewed twice. PLHIV
participants had been on ART for a mean of twenty months at
the time of the first interview, and there was a mean of eight
months between the first and the last interview (see Table 1).
Additionally, 20 HCW participants were interviewed once (see
Table 2).
Figure 1 depicts a summary of the study findings, which are
elaborated as follows.
3.2 | The perceived need for treatment influencing
engagement with treatment and care
For PLHIV, perceiving need for treatment was important to
motivate their taking it. For some, receiving an HIV diagnosis
was itself a pointer to the need for treatment: “I had heard
that if you are positive and do not take the treatment you
could die. . .” (Nozipho, woman, 19 years). Although clinically
asymptomatic, some participants described embodied signs of
HIV which served to warn them of the potential risk of deteri-
orating health:
I started taking the treatment because I am afraid of get-
ting sick and even at times I would have headache, and I
would think probably it has started. (Sifiso, man,
41 years)
Some believed that treatment would prolong their life. This
was particularly described by men living with HIV, with early
initiation of treatment seen as enabling maintenance of
strength and productivity, potentially reinforcing notions of
masculine responsibility. Additionally, several PLHIV described
experiencing physical changes after starting ART, such as
increased energy and strength, increased weight and feeling
healthier, for example no longer experiencing headaches. This
Table 1. PLHIV participant characteristics (n = 17)a
Gender
Female 9
Male 8
Age
Young adult
17 to 20 years 4 (all women)
21 to 25 years 3 (all women)b
Adult
26 to 39 years 5 (1 woman, 4 men)
40 to 49 years 5 (1 woman, 4 men)
Enrolment to Treat-all
Oct 2014 to Dec 2014 5
Jan 2015 to Mar 2015 8
April 2015 to June 2015 4
Time between enrolment and initiation
Same day 4
1 to 6 days 5
7 to 10 days 1
Ten days to one month 3
One to three months 2
Four to eight months 2
Treatment category
On ART 10
Lost from treatmentc 7
aParticipant information relates to that recorded on the project
patient database at the time of recruitment. bYoung adults (aged 16
to 25 years) and adults (aged 26 to 49 years) were purposively
included in the sample. No young men were eligible due to the epi-
demiology of HIV in Swaziland meaning less young men are infected,
and additionally men can access care later. cLost from treatment
defined as those with a last recorded visit date of at least four
months from the time of sample selection (to allow for those with
three monthly refills).
Table 2. HCW participant characteristics (n = 20)
Position
Adherence counsellor 5
Nurse/nurse supervisor 13
Doctor 1
Employer
MoH 12
MSF 8
Facility
Primary Health Clinic (8 clinics included) 17
Secondary Health Facility 3
HCW, healthcare worker; MSF, Medecins Sans Frontieres; MoH,
Ministry of Health.
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reinforced a sense of value to the treatment and motivated
continued treatment-taking:
It is helping . . . because most of the time before I started
taking the treatment I would feel that my body is going
down, like when you wake up you’d find that the body is
very tired most of the time. But then since I started the
treatment I feel much better and healthier, and my body is
energetic (Mandla, man, 36 years)
3.3 | Doubts about treatment need and effect
undermining treatment-taking
However, not all participants perceived themselves as needing
treatment or believed that it could benefit them. Several
described doubts about the need for treatment in the absence
of symptoms or signs of ill health:
The CD4 is high and it is just the positive word that is
pointing, there are no other signs . . . I will take them when
I can see that it [HIV] is now really there. (Zandile, woman,
23 years)
Some patients tell you that there is no need, they will start
the treatment when they are sick, not now. (HCW15)
Those who did not experience any changes with ART
appeared to doubt its effectiveness and the difference that
treatment was making to them, which could undermine their
motivation for taking it.
The problem I have is that I haven’t seen the effective-
ness of the treatment, because even when I go to the
hospital the weight scale doesn’t reflect much of a
change . . . nothing changed because when I went there I
wasn’t sick, but I just went there healthy. (Jabulane,
man, 31 years)
These doubts could also change over time, as participants
sought evidence of the treatment’s effectiveness and inter-
preted their own experiential changes as suggesting the treat-
ment was working. For example, Jabulane, quoted from his
second interview above, went on to interpret his health as
improving by the third interview:
With the pills my brother, the way I see it, they are working
because . . . I used to have flu every now and then . . . that
is when I eventually got tested, but then since I started tak-
ing the treatment I no longer have such, I don’t get influ-
enza and go to the hospital.
Where doubts about treatment need and effectiveness
were present, these appeared linked to PLHIV developing a
sense of treatment fatigue over time:
I used to just get tired and I would sometimes skip some
days and not go to collect them . . . there were times I just
would be quiet and not take it, not because there is no food
or something, I would just feel annoyed that why am I tak-
ing this treatment and what is it for? (Khanyisile, woman,
24 years)
Seeking evidence of treatment 
need and eﬀect
Reinterpreng past illnesses 
as signs of HIV
HIV diagnosis – belief, 
acceptance, treatment need
Viral load monitoring results –
eﬀect of treatment on virus
Embodied physical changes on 
ART e.g. energy, weight, strength
Not sick – not feeling sick or 
idenfying as needing ART
Doubts about HIV diagnosis 
accuracy Experimenng No physical changes on ART 
Supporng treatment-taking
Undermining treatment-taking
Figure 1. Diagram of findings relating to seeking evidence of treatment need and effect and their influence on treatment-taking.
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HCW also described such doubts and treatment fatigue as a
reason for some PLHIV disengaging from treatment and care:
After some years . . . you can find that a patient would say
‘ahh this treatment, I’m not sick anyway’ . . . so they believe
they should stop the medication. (HCW10)
3.4 | Seeking evidence of the treatment’s
effectiveness
Almost all PLHIV participants described wanting to see the
difference that treatment was making to the virus and their
health prognosis. Some also described a desire to hear more
about their blood tests:
I want them to tell me is there something that it is doing, is
there a difference. Even now I want them to tell me how
my CD4 is doing, my CD4 was this much and now that I
am continuing with the treatment, is it making any differ-
ence? (Celiwe, woman, 40 years)
For those who were informed of suppressed viral load
results, this appeared to instil a belief in the effectiveness of
treatment, which could be particularly important for those
who initiated ART in the absence of symptoms, and which was
said to motivate ongoing treatment-taking: “[When told sup-
pressed] it made me to feel free and to continue emphatically
taking the treatment, because it means it is working.” (Vusi,
man, 49 years)
The role of viral load monitoring as a potentially important
tool for supporting adherence among patients who initiate
ART when healthy under the Treat-all policy was reiterated by
HCW participants:
These patients are patients who came in healthy, they had
no symptoms, so they are going to continue being healthy
. . . they are not going to see what is better for them. So
viral suppression is important . . . It would actually be good
to have an initial baseline viral load and then you do moni-
toring following. (HCW19)
HCW recognized the importance of time explaining results:
I can admit and say we don’t give that oomph for that time
as equal as when the viral load is unsuppressed . . . yes we
don’t give that attention, maybe we can strengthen and say
yes even if the patient’s viral load is suppressed . . . CD4
count is high . . . we need to sit with the patient. . . and try
to give the patient a lot of time and understanding.
(HCW09)
Certain participants who were doubtful about the need for
treatment and its effectiveness described experimenting with
treatment-taking, as a means of seeking such evidence:
There was a time . . . when I would think ‘haw this thing is
not doing anything to me’ and then I stopped taking them
and there was no sign of it being there . . . I never used to
take them . . . I was not taking them well and nothing
would happen and it would be the same as when I was tak-
ing them. (Nobuhle, woman, 17 years)
4 | DISCUSSION
This study investigated the experiences of asymptomatic
PLHIV engaging with HIV care under the Treat-all policy in
Eswatini. Our findings suggest that it is important for PLHIV
to have a sense of the difference treatment is making to them,
in terms of its influence on their virus and health prognosis.
Where PLHIV perceived need for treatment and believed it
was effective in improving their health and potentially pro-
longing life, this motivated treatment-taking and supported
engagement with care. On the other hand, doubts relating to
treatment need and effect could undermine engagement.
The biomedical logic framing Treat-all assumes that individu-
als will adjust their actions once they are educated; however,
treatment decisions surpass the biomedical realm [34]. There
can be dissonance between the biomedical rhetoric and lived
experiences of those who engage with technologies [35],
including in lay interpretations of what constitutes treatment
necessity [36]. In our study PLHIV could gain evidence of
treatment effect through experiential, embodied changes with
identifiable, physical improvements after being on ART, or
through viral load monitoring results showing the impact of
ART on the level of the virus. However, some PLHIV had
doubts about the need for treatment and its effectiveness in
the absence of any symptoms or signs of ill health, which
could undermine their engagement and cause intermittent
treatment-taking. While others have examined the factors
influencing ART initiation among asymptomatic PLHIV within
Treat-all [37-39], our study builds on these findings and pro-
vides insight into the influences on ongoing, longer term treat-
ment taking, after an average of 20 months on ART.
Existing evidence from Eswatini suggests PLHIV can find it
difficult to accept ART within Treat-all when feeling healthy,
with the belief that ART is for sick people [37,40]. Experiences
with Option-B+ programmes in Southern Africa have found
some relate taking ART with being ill or having a low CD4
count, which can undermine asymptomatic pregnant and lac-
tating women’s engagement with treatment [19,41]. Pound
et al. describe treatment-taking as a concretization of illness,
rather than health [42]. As HIV treatment for preventative
purposes within Treat-all transforms HIV from an acute to
chronic condition, the symptoms of disease and efficacy of
treatment become less apparent [43]. While some participants
in our study felt they did not need treatment in the absence
of symptoms, others reinterpreted past illnesses and physical
experiences such as fatigue, low energy and weight loss as
signs of HIV, which served to warn them of the potential
imminent health deterioration without treatment, thereby
motivating their engagement with care. Such reinterpretations
of past events as indications of HIV were also found by Zhou,
and influenced women’s ART initiation within Option-B+ [43],
suggesting the importance of experiential, embodied experi-
ence in treatment decisions. Certain participants in our study
felt that a HIV diagnosis itself pointed to the need for treat-
ment. These findings therefore highlight the ways in which
conceptions around health and treatment need are changing
within the context of Treat-all, and they may continue to do
so as it becomes more commonplace.
Almost all participants in our study wanted to see the positive
effect or difference treatment was making to them, seeking evi-
dence of the treatment’s effect either through their own
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embodied experiences or through biomarkers such as CD4
count and viral load, which served as indicators of their health
status. Although some researchers have described the value
placed on such indicators [44], our findings went further by sug-
gesting that viral load monitoring can play an important role in
supporting adherence to ART, offering patients a means to view
the effect of treatment on the level of the virus. This may be of
particular importance in Treat-all contexts where PLHIV are
increasingly initiating ART at earlier, asymptomatic phases of
the disease. Routine viral load monitoring should be imple-
mented universally as a tool to promote engagement in treat-
ment and care, with communication of both suppressed results,
as well as unsuppressed results, being emphasized.
Under previous treatment guidelines, recounting narratives
of illness history and comparing pre- and post-ART health could
motivate continued treatment-taking [12,13]. Although PLHIV
are now increasingly initiating ART when clinically asymp-
tomatic, findings from Option-B+ suggest that interpretations
of physical improvements on ART, in particular falling sick less
often, feeling more energetic and therefore more productive
can be important for supporting continued treatment-taking
[19,43,45]. Certain PLHIV in our study who did not experience
any such physical signs of HIV prior to starting ART, changes on
ART or viral load results presented doubts about the need for
treatment and its effectiveness. This could lead to treatment
experimentation, where PLHIV could miss doses of treatment,
seeking evidence of its effect. Conrad describes “non-compli-
ance” as a form of “self-regulation,” where patients may alter the
course of treatment to test its efficacy [46], as seen in mothers
enrolled in Option-B+ [43]. This is particularly problematic as it
poses risks for drug resistance [24], suggesting the importance
of patients within Treat-all starting treatment when they are
ready, when they want treatment and exploring means of
addressing their concerns about its effectiveness. PLHIV who
had such doubts were also said to be more likely to develop a
sense of treatment fatigue over time, where questioning the
point of treatment undermines the energy for taking it. This
could become increasingly relevant as Treat-all patients are on
treatment for longer periods of time.
4.1 | Limitations
As the Treat-all pilot was implemented by MSF and the MoH,
patients may have received more support, including greater
availability of viral load monitoring. However, the pilot aimed
to examine the feasibility of Treat-all under routine program-
matic conditions, and the presence of viral load monitoring
enabled unique insight into the supportive value of this tool
for patients’ treatment-taking. Though we were able to include
PLHIV who had been enrolled in Treat-all care for longer than
previously reported, Treat-all was still fairly new at the time of
this study. It will be important to examine how these findings
may change as Treat-all becomes more commonplace, as well
as to examine experiences of PLHIV with Treat-all who have
been on ART for longer.
5 | CONCLUSION
This research highlights the importance of PLHIV perceiving
need for treatment and having evidence of the benefits of
their taking it, for motivating their ongoing, sustained treat-
ment-taking in the context of Treat-all. Almost all partici-
pants described a desire for evidence of the need for
treatment and its effect, with routine viral load monitoring
potentially providing this. This could be particularly impor-
tant for those who initiate ART when asymptomatic, who do
not experience the transformative effects of ART and who
can have doubts about the value of treatment, which poten-
tially undermine treatment-taking. It is important that pro-
grammes consider these findings to adapt patient support,
to avoid the risk of PLHIV “experimenting” with treatment-
taking which could cause drug resistance to develop. This
could include communicating to patients that there may be
no notable difference in health status on initiating ART
when asymptomatic, and that benefits of early ART include
prolonging good health. Programmes should also ensure rou-
tine viral load monitoring is included as an integral compo-
nent of HIV care within the Treat-all policy, with a baseline
viral load if possible, and ensuring suppressed results are
communicated to patients.
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